CRDL · Cardiol Therapeutics Inc.

This 6-K filing reports a significant acceleration in Cardiol Therapeutics’ pivotal Phase III MAVERIC trial for recurrent pericarditis — a high-unmet-need cardiovascular indication with ~40,000 annual U.S. recurrences and substantial healthcare burden ($20,000–$30,000/hospitalization). The expansion to up to 25 clinical sites — anchored by elite cardiovascular institutions — reflects strong investigator conviction and directly addresses prior enrollment constraints. Reaching 75% enrollment by late April 2026, just months after crossing 50% in early January, signals meaningful momentum and de-risks the timeline: full enrollment remains targeted for end-Q2 2026, with only modest contingency into Q3 for newly activated sites. Critically, the trial design was pre-cleared by the FDA in April 2025, and its foundation in robust Phase II data (rapid symptom control, reduced recurrence rates) strengthens the probability of success. As the sole ongoing pivotal study for CardiolRx™ — a non-immunosuppressive oral therapy targeting inflammasome-driven inflammation — MAVERIC’s progress is the primary near-term value inflection point for investors. A successful readout would position Cardiol for an NDA submission, potentially enabling commercialization in a setting where current therapies are largely immunosuppressive, poorly tolerated, or inaccessible earlier in the treatment pathway. No financial, operational, or governance disclosures are included; materiality derives entirely from clinical execution velocity and regulatory alignment.